
|Articles|May 15, 2005
Site-active steroid provides symptomatic relief for patients with dry eye disease
Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
3
Study links alcohol consumption to earlier advanced presbyopia in men
4
Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)
5





















